Shots: Several undulating factors coalesce to inadvertently shape the biopharma industry Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list. Jesse Mendelsohn, SVP at Model N, emphasizes the…
Shots: Drug pricing reforms from the IRA continue to impact pharmaceutical companies. The rebates ensued from the IRA guidelines are heavily affecting the revenues of biopharma companies Today, at PharmaShots we have Jesse Mendelsohn, Sr. Vice President at Model N shedding light on the company’s recently launched solution called Medicare Part D inflation rebate-per-unit With…
Shots:Kyle started by giving a brief introduction to Model N’s Spring 2023 product release for life sciences and high-tech customers and discussed its key featuresHe then spoke about the challenges faced by the pharmaceutical industry due to duplicate discounts and how Model N’s 340B Vigilance Solution can address these challengesThe interview shows…
Shots:Suresh Kannan discussed the latest semi-annual update to bring innovative revenue optimization and compliance solution for life sciences and high-tech innovatorsHe elaborated on the Fall 2022 product release, providing customers with tools to improve automation, efficiency, and profitability during economic uncertainty along with streamlined pricing communicationThe interview gives an understanding of how…
Shots:Kyle Forcier gave a detailed view of the Spring 2022 product release by Model N and how it will be a practical solution for the Pharmaceutical and MedTech companiesKyle also spoke about Model N’s Revenue Cloud, which can empower MedTech Sales with better revenue recognitionThe interview gives a glimpse of Model N’s…

